To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - Transactions by persons discharging managerial responsibilities and persons closely associated with them

Release Date: 30/04/2018 07:05
Code(s): MEI     PDF:  
Wrap Text
Transactions by persons discharging managerial responsibilities and persons closely associated with them

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company” or the “Group”)

27 April 2018

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

On 8 and 10 January 2018, the Waledro Trust, a testamentary trust of which Dr Edwin Hertzog,
chairman of the Board of directors of Mediclinic, is the sole trustee, transferred its entire holdings in
the Company to the beneficiaries of the trust at the cost price. Dr Hertzog is not a beneficiary of the
trust.

The notification below is made in accordance with Articles 19.1 and 19.3 of the Market Abuse
Regulation.

  1.       Details of PDMR / person closely associated with them (“PCA”)

  a)       Name                     Waledro Trust

  2.       Reason for the notification

  a)       Position / status        The Waledro Trust is a testamentary trust of which Dr Edwin
                                    Hertzog, chairman of the Board of directors of the Company, is
                                    the sole trustee. Dr Hertzog is not a beneficiary of the trust.

  b)       Initial notification /   Initial Notification
           amendment
  3.       Details of the issuer, emission allowance market participant, auction platform, auctioneer or
           auction monitor

  a)       Name                     Mediclinic International plc

  b)       LEI                      2138002S5BSBIZTD5I60

  4.       Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
           type of transaction; (iii) each date; and (iv) each place where transactions have been
           conducted

  a)       Description of the       Ordinary Shares
           financial instrument

           Identification Code      GB00B8HX8Z88

  b)       Nature of the            Transfer of shares to beneficiaries of trust at the cost price.
           transaction

  c)       Price(s) and
           volume(s)                 Price(s)                          Volume(s)
                                     ZAR 200.08 per share              13,281
  d)       Aggregated
           information

           Aggregated volume         13,281

           Price                     ZAR 200.08


  e)       Date of the               8 January 2018
           transaction

  f)       Place of the              Johannesburg Stock Exchange
           transaction

  4.       Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
           type of transaction; (iii) each date; and (iv) each place where transactions have been
           conducted

  a)       Description of the        Ordinary Shares
           financial instrument

           Identification Code       GB00B8HX8Z88

  b)       Nature of the             Transfer of shares to beneficiaries of trust at the cost price.
           transaction

  c)       Price(s) and
           volume(s)                 Price(s)                         Volume(s)
                                     ZAR 200.08 per share             2

  d)       Aggregated
           information

           Aggregated volume         2

           Price                     ZAR 200.08


  e)       Date of the               10 January 2018
           transaction

  f)       Place of the              Johannesburg Stock Exchange
           transaction



About Mediclinic International plc

Mediclinic is an international private healthcare services group, established in South Africa in 1983,
with current operating divisions in Southern Africa (South Africa and Namibia), Switzerland and the
United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute
care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9%
interest in Spire Healthcare Group plc, a LSE listed and UK-based private healthcare group.

Mediclinic comprises 75 hospitals and 33 clinics. Mediclinic Southern Africa operates 49 hospitals and
2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds
in total; Hirslanden operates 17 hospitals and 4 clinics in Switzerland with more than 1 700 inpatient
beds; and Mediclinic Middle East operates 6 hospitals and 27 clinics with more than 700 inpatient
beds in the United Arab Emirates.
Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary
listings on the JSE in South Africa and the NSX in Namibia.


For further information, please contact:

Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries
FTI Consulting
Brett Pollard/Debbie Scott – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000


Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc
JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd

Date: 30/04/2018 07:05:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story